Investors

Corporate Profile

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.

We believe EG-1962, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. Read More

Lastest News

September 8, 2016 - Edge Therapeutics to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series and Participate in Additional Investor Conferences in September
Read More
September 6, 2016 - Edge Therapeutics Announces Additional Pharmacokinetic Data Supporting the Potential Clinical and Health Economic Impact of EG-1962 in Aneurysmal Subarachnoid Hemorrhage
Read More
September 1, 2016 - Edge Therapeutics to Present Additional Data from Phase 1/2 NEWTON Study of EG-1962 at Two Scientific Conferences in September
Read More

Upcoming Events

There are currently no events scheduled.

Stock Information

EDGE (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$11.06
Change (%) Stock is Down 0.24 (2.12%)
Volume17,062
Data as of September 23, 2016 4:00 p.m. ET
Refresh quote

IR Contact

Gregory Gin
Email: ir@edgetherapeutics.com

Data provided by Nasdaq. Minimum 15 minutes delayed.

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR ContactsDownload Financial Tear Sheet Financial Tear Sheet